FDA Approved: ONIVYDE — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ONIVYDE (liposomal irinotecan), submitted by Ipsen Biopharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

SUPPL AP for ONIVYDE (IRINOTECAN HYDROCHLORIDE)